SCM
ICPT

Stonepine Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Stonepine Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-18,600
Closed -$1.08M – 32
2017
Q3 		$1.08M Buy
+18,600
New +$2M 0.64% 18

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Stonepine Capital Management's ICPT Position: Q4 2017 in Review

Stonepine Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2017, closing a stake of 18,600 shares — an estimated $1.08M sold.

Stonepine Capital Management first reported a position in ICPT in Q3 2017 and held it in 1 quarter. The position peaked at $1.08M in Q3 2017. 168 funds tracked by Wall St. Rank hold ICPT as of Q4 2017.

  • Stonepine Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Stonepine Capital Management sold 18,600 Intercept Pharmaceuticals, Inc. shares in Q4 2017, an estimated $1.08M.
  • Stonepine Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2017 and held it in 1 quarter.
  • Stonepine Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $1.08M in Q3 2017.
  • 168 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2017.

Based on Stonepine Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.